Synthesis and evaluation of camphor and Cytisine (cas 15191-27-2)-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus

Add time:08/04/2019    Source:sciencedirect.com

In this study, bornyl- and cytisine-based cyanopyrrolidines as potent dipeptidyl peptidase-IV (DPP-IV) inhibitors were synthesised. The in vitro inhibiting activities of bornyl- and cytisine derivatives towards DPP-IV were evaluated. Bornyl-based cyanopyrrolidines were shown to have moderate inhibitory activity with regard to DPP-IV (1.27–15.78 µM). A docking study was performed to elucidate the structure-activity relationship of the obtained compounds. The in vivo hypoglycemic activities of the same compounds were evaluated with the oral glucose tolerance test (OGTT) in mice. Bornyl-based cyanopyrrolidines were shown to have good hypoglycemic activity.

We also recommend Trading Suppliers and Manufacturers of Cytisine (cas 15191-27-2). Pls Click Website Link as below: cas 15191-27-2 suppliers

Prev:Cytisine (cas 15191-27-2) basicity, solvation, log P, and log D theoretical determination as tool for bioavailability prediction
Next:Crystal structure, spectral and thermal properties of 1,2-bis[2-(4,4,4-trifluoro-1-hydroxy-3-oxobut-1-enyl)phenoxy]-ethane and luminescent properties of its complexes with Al(III) and Eu(III))